NanoViricides completed a registered direct offering that raised $6 million by selling 3.57 million shares of common stock at $1.68 per share. The transaction also issued Series A and Series B warrants, each covering up to 3.57 million shares. Series A warrants can be exercised six months after issuance at $1.75 per share and expire two years later, while Series B warrants are exercisable after six months at $2.00 per share and expire five and a half years later. The $2.00 exercise price for Series B warrants represents a roughly 20 % premium to the company’s closing share price on November 10, 2025.
The proceeds are earmarked for working capital and general corporate purposes, with a primary focus on supporting the company’s ongoing clinical development. At the close of June 2025, NanoViricides held about $1.67 million in cash and was debt‑free, leaving it with less than a year of runway based on its current free‑cash‑flow profile. The new capital injection is therefore expected to extend that runway and provide the liquidity needed to advance its lead candidate, NV‑387, into Phase II trials.
NanoViricides’ auditor issued a “going concern” warning in its most recent financial statements, citing the company’s limited cash balance and high burn rate. The warning underscores the urgency of the financing, as the company’s cash position could become untenable without additional capital. The $6 million raise directly addresses this risk by bolstering liquidity and reducing the likelihood of a liquidity shortfall.
On November 10, 2025, the U.S. Food and Drug Administration granted NanoViricides approval to initiate a Phase II clinical trial of NV‑387 for the treatment of MPox in the Democratic Republic of Congo. The trial approval is a critical regulatory milestone that could accelerate the drug’s development timeline and open the door to future funding opportunities. President and Executive Chairman Anil R. Diwan described the approval as an “important milestone” and emphasized that NV‑387 “is poised to revolutionize the treatment of viral diseases, just as antibiotics revolutionized bacterial treatment.”
NanoViricides remains a pre‑revenue company, and the $6 million direct offering represents one of the largest financing events it has undertaken to date. By securing additional capital, the company positions itself to sustain its clinical program, mitigate cash‑flow risk, and pursue the next phases of development for NV‑387 without the immediate pressure of external debt or equity dilution beyond the warrant issuance.
The financing event, coupled with the recent regulatory approval, places NanoViricides on a clearer path toward advancing NV‑387 through the clinical pipeline. The company’s debt‑free balance sheet and the new capital infusion provide a stronger foundation for pursuing future milestones, potentially improving its prospects for securing additional funding or partnerships as the drug progresses toward regulatory approval.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.